Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Authors
Van Akkooi, A. C. J.Hauschild, A.
Long, G. V.
Mandalà, M.
Kicinski, M.
Govaerts, A. S.
Klauck, I.
Ouali, M.
Lorigan, Paul C
Eggermont, A. M.
Affiliation
Melanoma Institute Australia, Wollstonecraft, AustraliaIssue Date
2023
Metadata
Show full item recordCitation
Van Akkooi ACJ, Hauschild A, Long GV, Mandalà M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005520.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS9601Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9601Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS9601